Clinical Trial Finder

Be a part of the movement transforming the future of cystic fibrosis treatment.

Clinical trials are listed below.

  • OtherEnrolling Location: Australia

    Does tiotropium bromide lead to bronchodilation in cystic fibrosis? , protocol number ACTRN12605000728639

    Does tiotropium bromide lead to bronchodilation in cystic fibrosis?

    • Age:

      Not Specified

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherNot yet recruiting Location: Australia

    Phase 3, placebo-controlled, parallel group randomised trial of the effect of nebulised hypertonic saline on the length of stay of people hospitalised with acute exacerbations of cystic fibrosis lung disease. , protocol number ACTRN12605000780651

    Phase 3, placebo-controlled, parallel group randomised trial of the effect of nebulised hypertonic saline on the length of stay of people hospitalised with acute exacerbations of cystic fibrosis lung disease.

    • Age:

      >17 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherNot yet recruiting Location: Australia

    Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four time daily to people with cystic fibrosis. , protocol number ACTRN12606000053527

    Pilot trial of the tolerability of hypertonic saline when delivered by a high-output nebuliser twice or four time daily to people with cystic fibrosis.

    • Age:

      No limit

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      >40% pred.

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Anti-InfectiveEnrolling Location: Australia

    A comparative assessment of the clinical impact , protocol number ACTRN12607000349448

    This study is designed to provide vitally needed information on the clinical implications of being infected by a clonal strain of P. aeruginosa and the risk factors for the acquisition of a clonal strain. This new information will provide a rational basis for the need for changes to infection control policies and better outcome predictors for patients infected with clonal strains of P. aeruginosa.

    • Age:

      2-75 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • BehavioralEnrolling Location: Australia

    Engaging and re-connecting 'at-risk' children with chronic respiratory illness. , protocol number ACTRN12607000515493

    Children with chronic illness sometimes feel disconnected and lonely. In this study we will evaluate the use of a psycho-social intervention program for 'at-risk' children (ie. child with chronic illness, low socio-economic groups) to improve their sense of well-being, adherence to therapies and health outcomes.

    • Age:

      10-15 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      Not Specified

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • OtherEnrolling Location: Australia

    Effect of a targetted exercise program versus current exercise practice on function, activity and participation of young people with cystic fibrosis: a randomised, controlled trial , protocol number ACTRN12607000612415

    Exercise is a vital component of the physiotherapy management for young people with cystic fibrosis (CF). The overall aim of this research is to strengthen knowledge about best practice exercise programs for this population. This study compares effects of two exercise programs (the current exercise practice versus a novel targeted exercise program). Ultimately, it is expected that with improved exercise programs, young people with CF may have improved body structure and function, and activity and participation levels, leading to enhanced quality of life.

    • Age:

      18-70 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      40% predicted or above

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • BehavioralNot yet recruiting Location: Australia

    Stretching in cystic fibrosis: does it improve the quality of life and measures of kung function. , protocol number ACTRN12608000484347

    Stretching in cystic fibrosis: does it improve the quality of life and measures of kung function.

    • Age:

      18-70 years

    • Mutation(s):

      Not specified

    • FEV1% Predicted:

      >40% or above

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • ObservationalEnrolling Location: Multiple US sites

    Rare Mutation Cell Collection (RARE) , protocol number NCT 03161808 NCT 03161808

    This study is taking place at multiple care centres across the US. Researchers will collect and make available for study cells from people with rare CFTR mutations.

    • Age:

      2 years and older

    • Mutation(s):

      No mutation requirement

    • FEV1% Predicted:

      40-90%

    • Number of Visits:

      8

    • Length of Participation:

      30 days

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation , protocol number VX14-809-109 NCT02514473

    A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

    • Age:

      6-11 years

    • Mutation(s):

      homozygous for the F508del CFTR mutation

    • FEV1% Predicted:

      ppFEV1 of ≥70 p

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Restore CFTR FunctionEnrolling Location: Australia

    Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation) (SAPHIRA1) , protocol number NCT02707562

    A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation

    • Age:

      >18 years

    • Mutation(s):

      G551D

    • FEV1% Predicted:

      Pre- or post-bronchodilator FEV1 ≥ 40% of predicted normal

    • Number of Visits:

      Not specified

    • Length of Participation:

      Not Specified

    Contact us about this clinical Trial >
  • Displaying results 31-40 (of 142)
     |<  <  1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >|